Table 4.

Comparison of demographic, clinical, and laboratory screening variables at the end of three months.

	Survivors (n =26)	Nonsurvivors (n = 22)	p value
Demographic
Age	55.3 (±12.1)	54.1 (±9.5)	0.726
Men	17 (65.4%)	16 (72.7%)	0.584
Women	9 (34.6%)	6 (33.3%)
Clinical
Child-Pugh	9.7(±2.1)	10.9(±1.8)	0.046
MELD	19.3 (±6.1)	24.6 (±7.6)	0.012
MELD-Na	21.7 (±6.6)	27.5 (± 6.2)	0.03
ICA-AKI Stage
1	17 (65.4%)	10 (56.3%)	0.259
2	6 (23.1%)	10 (45.5%)
3	3 (11.5%)	2 (9.1%)
Subdivision of stage 1 (n=28)
1a	5 (29.4%)	2 (20%)	0.678
1b	12 (70.6%)	8 (80%)
AKI causes
Infection	10 (38.5%)	10 (45.5%)	0.058
Hypovolemia	9 (34.6%)	6 (27.3%)
Hepatorenal syndrome	0	4 (18.2%)
Nephropathy	2 (7.7%)	0
Miscellaneous	1 (3.8%)	2 (9.1%)
Multiple	4 (15.4%)	0
Response to expansion treatment			<0.0001
Complete	20 (76.9%)	7 (31.8%)
Partial	5 (19.2%)	3 (13.6%)
Absent	1 (3.8%)	12 (54.5%)
Encephalopathy
Present	6 (23.1%)	7 (31.8%)	0.361
Absent	20 (76.9%)	15 (68.2%)
Ascites
Present	21 (80.8%)	12 (90.9%)	0.532
Absent	5 (19.2%)	2 (9.1%)
Laboratory
Creatinine (mg/dL)	2.0(±0.9)	2.2(±2.2)	0.525
Total bilirrubin (mg/dL)	1.6 (0.3-15.2)	5 (0.4-23.9)	0.020
Albumin (g/dL)	2.4 (±0.5)	2.6 (±0.5)	0.368
INR	1.5(1-3)	1.9(1.1-7)	0.067
Sodium (mEq/L)	134.1 (±5.2)	133.4 (±5.2)	0.681
C-Reactive Protein (mg/L)	30.4 (5-278)	31.6(5-278)	0.869

ICA-AKI, International Club of Ascites–Acute Kidney Injury.